ArticleOncotarget2017

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab.

Renata Duchnowska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.